Invesco Ltd. 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-10 2:09 pm Sale | 2023-07-10 | 13G | Nektar Therapeutics NKTR | Invesco Ltd. IVZ | 5,535,430 2.900% | -31,792,043 (-85.17%) | Filing |
| 2023-02-02 3:19 pm Purchase | 2023-02-02 | 13G | Nektar Therapeutics NKTR | Invesco Ltd. IVZ | 37,327,473 19.900% | 435,979 (+1.18%) | Filing |
| 2022-02-11 12:22 pm Purchase | 2022-02-11 | 13G | Nektar Therapeutics NKTR | Invesco Ltd. IVZ | 36,891,494 20.000% | 1,434,545 (+4.05%) | Filing |
| 2021-02-12 2:53 pm Purchase | 2021-02-12 | 13G | Nektar Therapeutics NKTR | Invesco Ltd. IVZ | 35,456,949 19.800% | 3,827,815 (+12.10%) | Filing |
| 2020-02-07 4:09 pm Sale | 2020-02-06 | 13G | Nektar Therapeutics NKTR | Invesco Ltd. IVZ | 31,629,134 18.000% | -3,014,252 (-8.70%) | Filing |